Stockreport

Assessing Erasca (ERAS) Valuation After Encouraging Early ERAS-0015 Data At JP Morgan Conference [Yahoo! Finance]

Erasca, Inc.  (ERAS) 
PDF responses at low doses in the Phase 1 AURORAS-1 trial, with no dose-limiting toxicities reported. See our latest analysis for Erasca. The early ERAS-0015 data has li [Read more]